|
Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study. |
|
|
|
Consulting or Advisory Role - Roche; Roche |
Travel, Accommodations, Expenses - Roche; Roche |
|
|
Honoraria - Janssen; Roche |
Consulting or Advisory Role - Janssen; Roche |
Speakers' Bureau - Janssen; Roche |
Research Funding - Bayer; Janssen; Roche |
|
|
Honoraria - Celgene; Gilead Sciences; Janssen; Roche; Sanofi |
Consulting or Advisory Role - Celgene; Roche |
Travel, Accommodations, Expenses - Gilead Sciences; Janssen; Roche; Sanofi |
|
|
Stock and Other Ownership Interests - OVIBIO |
Consulting or Advisory Role - OVIBIO |
Research Funding - 4SC (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Sanofi (Inst) |
|
|
Honoraria - Abbvie; Roche Pharma AG; Sandoz; TEVA |
Speakers' Bureau - Kite/Gilead; Kite/Gilead; Teva |
Research Funding - Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bioinvent (Inst); Gilead Sciences (Inst); Roche (Inst) |
|
|
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Celgene; Gilead Sciences; Janssen; Roche/Genentech; TG Therapeutics |
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Celgene; Janssen |
Research Funding - Acerta Pharma/AstraZeneca; Celgene; Janssen |
|
|
Employment - Roche Shanghai |
|
|
|
Stock and Other Ownership Interests - Alkahest; Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
|
|
Honoraria - Bayer; Celgene; Janssen; Roche |
Consulting or Advisory Role - Celgene; Janssen; Roche |
Speakers' Bureau - Celgene; Janssen; Roche |
Research Funding - Celgene; Janssen; Roche |
Travel, Accommodations, Expenses - Celgene; Janssen; Roche |
|
|
No Relationships to Disclose |